Director/PDMR Shareholding

1 May 2019 12:00 BST

Transactions by Persons Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 29 and 30 April 2019, it was notified of transactions in the Company's ordinary shares of $0.25 each (Ordinary Shares) and American Depositary Shares (ADSs) by certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) as set out below. Two ADSs are equivalent to one Ordinary Share.

PDMR Position Nature of the transaction Quantity Price
Pascal   Soriot Chief Executive Officer Purchase of Ordinary Shares 17,100 GB£58.255
Philip   Broadley Non-Executive Director Purchase of Ordinary Shares 520 GB£57.38
Sheri   McCoy Non-Executive Director Purchase of ADSs 2,372 US$38.1783
Sheri   McCoy Non-Executive Director Purchase of ADSs 100 US$38.172
Deborah   DiSanzo Non-Executive Director Purchase of ADSs 1,000 US$38.3056

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

1  Details   of the person discharging managerial responsibilities / person closely   associated 
a)  Name  Pascal   Soriot
2  Reason   for the notification 
a)  Position/status    Chief   Executive Officer
b)   Initial   notification /Amendment  Initial   notification
3  Details   of the issuer, emission allowance market participant, auction platform,   auctioneer or auction monitor 
a)  Name  AstraZeneca   PLC
b)   LEI  PY6ZZQWO2IZFZC3IOL08
4  Details   of the transaction(s): section to be repeated for (i) each type of   instrument; (ii) each type of transaction; (iii) each date; and (iv) each   place where transactions have been conducted 
a)  Description   of the financial instrument, type of instrument   Identification   code Ordinary   Shares of US$0.25 each in AstraZeneca PLC     GB0009895292   
b)   Nature   of the transaction  Share   purchase
c)  Price(s)   and volume(s)                                 Price(s)           Volume(s)       GB£58.255       17,100   
d)  Aggregated   information   -   Aggregated volume     -   Price    Not   applicable - single transaction 
e)  Date   of the transaction  29 April   2019
f)  Place   of the transaction  XLON

 

1  Details   of the person discharging managerial responsibilities / person closely   associated 
a)  Name  Philip   Broadley
2  Reason   for the notification 
a)  Position/status    Non-Executive   Director
b)   Initial   notification /Amendment  Initial   notification
3  Details   of the issuer, emission allowance market participant, auction platform,   auctioneer or auction monitor 
a)  Name  AstraZeneca   PLC
b)   LEI  PY6ZZQWO2IZFZC3IOL08
4  Details   of the transaction(s): section to be repeated for (i) each type of   instrument; (ii) each type of transaction; (iii) each date; and (iv) each   place where transactions have been conducted 
a)  Description   of the financial instrument, type of instrument   Identification   code Ordinary   Shares of US$0.25 each in AstraZeneca PLC     GB0009895292   
b)   Nature   of the transaction  Share   purchase
c)  Price(s)   and volume(s)                                 Price(s)           Volume(s)       GB£57.38       520   
d)  Aggregated   information   -   Aggregated volume     -   Price    Not   applicable - single transaction 
e)  Date   of the transaction  30 April   2019
f)  Place   of the transaction  XLON

 

1  Details   of the person discharging managerial responsibilities / person closely   associated 
a)  Name  Sheri   McCoy
2  Reason   for the notification 
a)  Position/status    Non-Executive   Director
b)   Initial   notification /Amendment  Initial   notification
3  Details   of the issuer, emission allowance market participant, auction platform,   auctioneer or auction monitor 
a)  Name  AstraZeneca   PLC
b)   LEI  PY6ZZQWO2IZFZC3IOL08
4  Details   of the transaction(s): section to be repeated for (i) each type of   instrument; (ii) each type of transaction; (iii) each date; and (iv) each   place where transactions have been conducted 
a)  Description   of the financial instrument, type of instrument   Identification   code AstraZeneca   PLC American Depositary Shares     CUSIP:   046353108 
b)   Nature   of the transaction  Purchase   of AstraZeneca PLC American Depositary Shares
c)  Price(s)   and volume(s)                                               Price(s)           Volume(s)       US$38.1783       2,372       US$38.175       100   
d)  Aggregated   information   -   Aggregated volume     -   Price      2,472US$38.178
e)  Date   of the transaction  29 April   2019
f)  Place   of the transaction  NYSE

 

1  Details   of the person discharging managerial responsibilities / person closely   associated 
a)  Name  Deborah   DiSanzo
2  Reason   for the notification 
a)  Position/status    Non-Executive   Director
b)   Initial   notification /Amendment  Initial   notification
3  Details   of the issuer, emission allowance market participant, auction platform,   auctioneer or auction monitor 
a)  Name  AstraZeneca   PLC
b)   LEI  PY6ZZQWO2IZFZC3IOL08
4  Details   of the transaction(s): section to be repeated for (i) each type of   instrument; (ii) each type of transaction; (iii) each date; and (iv) each   place where transactions have been conducted 
a)  Description   of the financial instrument, type of instrument   Identification   code AstraZeneca   PLC American Depositary Shares     CUSIP:   046353108 
b)   Nature   of the transaction  Purchase   of AstraZeneca PLC American Depositary Shares
c)  Price(s)   and volume(s)                                 Price(s)           Volume(s)       US$38.3056       1,000   
d)  Aggregated   information   -   Aggregated volume     -   Price    Not   applicable - single transaction   
e)  Date   of the transaction  29 April   2019
f)  Place   of the transaction  NYSE

About AstraZeneca 

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Gonzalo Viña UK/Global +44 203 749 5916
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Jennifer Hursit UK/Global +44 203 749 5762
Christina M Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharma - Cardiovascular;   Metabolism +44 203 749 5711
Nick Stone BioPharma - Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Kretzmann Retail Investors; Corporate Access +44 203 749 5824
US toll-free +1 866 381 72 77

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links